Introduction
-
the general oncologic characteristics of the malignant disease and its former or current therapy (the organ affected, histologic type, molecular oncologic characteristics, grade and stage of tumour, therapy applied, stage of remission, time of survival since therapy);
-
the specifications of the planned hormone substitution therapy (estrogenic and progestagenic compound type, dose, sequential or continuous fixed combination regimen, route of administration, duration of MHT);
-
and the oncologically relevant endocrine caracteristics of the tumour, e.g. hormone receptor status (presence of hormone receptors, receptor subtypes, receptor splice variants, or estrogen-related receptors), former or current endocrine oncotherapy (aromatase inhibitors, selective estrogen receptor modulators, selective estrogen receptor degrader, GnRH analogues) or the effect of female hormones on the given tissue in general, or on the specific tumour type in particular. It is even possible, that in vivo HRT exerts its effect on tumour recurrence and progression (even contradicting in vitro results on isolated cells or tumour tissues) not by affecting the malignant cells themselves, but rather influencing for example the surrounding stromal tissue, the immune response of the body, or cells and structures participating in metastatization.
Determinants of Estrogen Effect on Tissues
Determinants of Progesterone Effect on Tissues
Childhood cancer | Young adult cancer | Female cancer (new cases) |
---|---|---|
Leukemia | Breast cancer | Breast cancer |
Brain and spinal cord tumours | Lymphoma (Hodgkin / non-Hodgkin) | Lung cancer |
Neuroblastoma | Melanoma | Colorectal cancer |
Wilms tumour | Sarcoma | Uterine corpus |
Lymphoma (Hodgkin / non-Hodgkin) | Female genital tract cancers | Thyroid cancer |
Rhabdomyosarcoma | Thyroid cancer | Non-Hodgkin lymphoma |
Retinoblastoma | Testicular cancer | Melanoma |
Bone cancer (osteosarcoma, Ewing sarcoma) | Colorectal cancer | Leukemia |
Leukemia | Pancreatic cancer | |
Brain and spinal cord tumours | Kidney cancer |
Breast Cancer
-
If breasts are intact and there is no history of breast cancer: in both BRCA1 and BRCA2 mutants, MHT can be offered to the age of natural menopause (50 years of age).
-
If prophylactic mastectomy has been performed but there is no history of breast cancer, MHT should be offered to the age of natural menopause.
-
If the patient had breast cancer, MHT is contraindicated.
-
In a recent international cohort study of BRCA-1 mutation women after prophylactic oophorectomy and with intact breast, the risk of breast cancer was found elevated when estrogen-progestin HRT was applicated, but the risk did not increase with estrogen-only therapy. This finding is in accordance with the observations with MHT and breast cancer risk in the natural menopause, and raise the indication of removing the uterus also at prophylactic oophorectomy in BRCA mutation women. [64]
Gynecologic Cancers
Ovarian Cancer
Endometrial Cancer
Uterine Sarcoma
Cervical Cancer
Vaginal and Vulvar Cancer
Non-gynecologic Tumours
Haematologic Malignancies
Brain Tumours
Prolactinoma
Malignant Melanoma
Lung Cancer
Colorectal Cancer
Kidney Cancer
Gastric Cancer
Liver Cancer
Bladder Cancer
Thyroid Cancer
Pancreatic Cancer
Conclusions
HRT: | Adavantageous | Neutral (no known negative effect) | Negative effect in certain setting (relative contraindication) | Disadvantageous (contraindicated) |
---|---|---|---|---|
Breast cancer | BRCA 1/2 mutation without breast cancer | Breast cancer | ||
Gynecologic cancers | Endometrial cancer (E2 dependent, type I) – E+P advantageous, E-only: neutral | • Endometrial cancer (E2 independent, type II) • Uterinal carcinosarcoma • Uterinal adenosarcoma | Leiomyosarcoma | Endometrial stroma sarcoma |
Ovarian cancer (epithelial, germ cell tumour) | Some ovarian tumours: • endometrioid ovarian cancer (?) • granulosa cell tumour | |||
Cervical adenocarcinoma (E+P) | Cervical cancer (squamous cell) | |||
Vaginal cancer (squamous cell) (adenocarcinoma??) | ||||
Vulvar cancer (squamous cell) (adenocarcinoma??) | ||||
Non-gynecologic cancers | Haematologic malignancies (leukaemias, lymphomas) | • Microprolactinoma • Macroprolactinoma (?? – close follow-up required if on HRT) | Brain tumours | • Meningioma • Glioma |
Malignant melanoma (local, cutaneous) | Malignant melanoma (advanced, metastatic) | |||
Colorectal cancer | Lung cancer | |||
Liver (hepatocellular) cancer | Kidney cancer | Gastric cancer | Gastric cancer (ER+, PR+) | |
Thyroid cancer | Bladder cancer | Bladder cancer (ER+) | ||
Pancreatic cancer |